Loxtidine hemisuccinate is a potent, long-acting H,-receptor antagonist under investigation as an anti-ulcer drug (Brittain & Jack, 1983). We have studied the metabolism of loxtidine hemisuccinate labelled with either 3H or I4C (Fig. I ).
I I4C lloxtidine base/kg body wt. In both species the compound was well absorbed with peak concentrations of loxtidine in plasma occurring within 1 h of dosing. Urinary excretion of radioactivity accounted for 5 6 7 5 % of the dose, most of which was excreted in 24 h. The balance of the radioactive dose was recovered in faeces. The urinary metabolites of radiolabelled loxtidine were examined by t.1.c. [silica-gel 60 F254, 0.2mm thick, developed in either ethyl acetate/propan-2-ol/water/ ammonia solution (sp. gr. 0.88) (25 : I5 : 8: 2, by vol.) or ethyl acetate/ethanol/ammonia solution (sp. gr. 0.88) (10: 2 : 1, by vol.)]. Authentic samples of synthetic loxtidine metabolites I, 111, IV and V (Fig. l) , used as reference standards, were detected on t.1.c. plates under U.V. light (254 nm). Radioactive metabolites were quantified by the use of a Berthold LB 2832 automatic t.1.c. linear analyser with an LB 3500 data system.
In rat the extent of loxtidine metabolism was dose-dependent. At doses of 2 and 50mg of IJ4CIloxtidine/kg body wt. the unchanged compound represented 20 and 75% respectively of the radioactivity excreted in 0-24 h urine. The major metabolite was the propionic acid derivative (IV; Fig. I) , which represented 55% of the urinary radioactivity after 2mg of 114CJ-loxtidine/kg body wt., but only 15%) after 50mg of II4CI-loxtidine/kg body wt. Confirmation of the N-dealkylation of loxtidine in rat was obtained by the recovery of a radiolabelled hydroxymethyltriazole metabolite (111) in urine after administration of [ 3H lloxtidine hemisuccinate. For a given dose level the proportions of metabolites 111 and IV were equivalent. 
BIOCHEMICAL SOCIETY TRANSACTIONS
The carboxylic acid metabolite (I) represented less than 5% of the urinary radioactivity after doses of either 2 or 50mg of I I4C Iloxtidine/kg body wt. to rat. A phenolic metabolite (V) was also present in trace amounts (less than 1% of urinary radioactivity). Incubation of rat urine with P-glucuronidase ( E . coli, type 11; Sigma) showed that the glucuronide conjugates of loxtidine (11) and the phenolic metabolite (VI) each represented less than 5% of the radioactivity excreted in urine.
In contrast with rat, the extent of loxtidine metabolism in dog was not dose-dependent. After oral administration of [ I4C 1-loxtidine hemisuccinate to dogs at 1-50mg of base/kg body wt. the unchanged compound comprised only about 20% of the urinary radioactivity. Glucuronidation of loxtidine was extensive and the conjugate (11) accounted for up to 75% of the dog urinary radioactivity after either dose. Only small amounts of the carboxylic acid (I) and propionic acid (IV) metabolites (less than 5% of urinary radioactivity) were seen in this species.
These results show important species differences in the metabolism of loxtidine. In the rat, phase I metabolism of loxtidine predominates. N-Dealkylation, the major metabolic pathway for the compound in this species, is apparently saturable at high dose levels. The phenolic metabolite (V) seen only in rat probably arises through 0-dealkylation of the propionic acid derivative (IV). In dog phase I metabolism of loxtidine is limited and the compound is extensively conjugated with glucuronic acid at both low and high doses. The metabolism of loxtidine in man is under investigation. The effect of dibutyryl cyclic AMP on bile-salt synthesis in isolated rat hepatocytes KATHLEEN M. BOTHAM and GEORGE S. BOYD* Department of Biochemistry, University of Edinburgh Medical School, Hugh Robson Building, George Square, Edinburgh EH8 9 X D , Scotland, U.K.
Recent reports have suggested that the activity of cholesterol 7a-hydroxylase, the rate-limiting enzyme in the degradation of cholesterol to bile salts, can be changed by alterations in its phosphorylation state (Sanghvi el al., 1981; Goodwin et al., 1982). In support of this, Margolis et al. (1981) found that 1 mM-dibutyryl cyclic AMP increases the incorporation of idea that the activity of this enzyme can be modulated by phosphorylation. In our laboratory, however, we have been unable to demonstrate any effect of cyclic AMP on cholesterol 7a-hydroxylase activity in rat liver microsomes in uitro (M. E.
Lawson, unpublished work). The synthesis of conjugated cholic acid in hepatocytes was increased about 2-fold by dibutyryl cyclic AMP (1 mM). Conjugated chenodeoxycholic acid synthesis was increased 10-20-fold, but production of its metabolite, conjugated P-muricholic acid, was decreased 30-50% in the presence of a similar concentration of the cyclic nucleotide (Table 1) . The ratio; Amount of conjugated cholic acid synthesized Amount of conjugated chenodeoxycholic acid + B-muricholic acid synthesized I ''Clcholesterol and I I4C]acetate into cholic and chenodeoxy-was therefore increased (50-100%) by 1 mwdibutyryl cyclic cholic acids in isolated hepatocytes. The mass of the two bile AMP. As this ratio is controlled by the enzyme 7a-hydroxysalts produced as measured by radioimmunoassay was also cholesten-4-en-3-one 12a-hydroxylase (Danielsson, 1973) . these increased. We have investigated the effects of dibutyryl cyclic results suggest that dibutyryl cyclic AMP increases the activity AMP, dibutyryl cyclic GMP and dibutyryl cyclic CMP on the ef this enzyme in isolated rat hepatocytes. It should be noted, synthesis of conjugated cholic acid and conjugated cheno-however, that hepatocyte levels of a-muricholic acid, an deoxycholic acid and its metabolite, conjugated P-muricholic intermediate in the formation of P-muricholic acid, were not acid, in isolated rat hepatocytes. measured in these experiments. The change caused by dibutyryl cyclic AMP in the ratio:
Amount of conjugated chenodeoxycholic acid synthesized by the cells Amount of conjugated P-muricholic acid synthesized by the cells Rat liver cells were prepared and incubated for 3 h at 37OC as described previously (Botham et al., 1980) . Where required, dibutyryl cyclic AMP, dibutyryl cyclic GMP or dibutyryl cyclic CMP was added in a small volume of the cell incubation buffer. The amounts of conjugated cholic, chenodeoxycholic and P-muricholic acid in the cell suspensions at zero time and after 3 h of incubation were determined by using radioimmunoassays (Beckett et al., 1978 (Beckett et al., , 1979 Botham et al., 1983) . Total bile-salt synthesis was calculated from the sum of the three individual bile-salt determinations.
Dibutyryl cyclic AMP ( 1 mM) increased total bile-salt synthesis in the hepatocytes by 30-50% (Table 1) . As the three bile salts measured represent at least 80% of bile salts present in rat liver in uiuo (Greim et al., 1972) , these results suggest that dibutyryl cyclic AMP stimulates bile-salt synthesis at the level of cholesterol 7a-hydroxylase. The findings are consistent with the * Deceased 10 January 1983. 
